CD19 and acute lymphoblastic leukemia: Furthermore, in NCT04796688, patients with CD19+ R/R ALL are being recruited to be treated with fludarabine + cyclophosphamide + CARNK-CD19 cells and evaluate the safety and efficacy of universal CAR-modified AT19 cells.